Keywords: good, start, germany, gpc, biotech, munich, germany-based
Good start to 2001 for Germany's GPC Biotech
Article | 23 May 2001
GPC Biotech, the Munich, Germany-based genomics company, has reported arevenue rise of almost 180% to 2.8 million euros ($2.5 million) for the first ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
